These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24120528)

  • 21. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.
    Dowling P; Clarke C; Hennessy K; Torralbo-Lopez B; Ballot J; Crown J; Kiernan I; O'Byrne KJ; Kennedy MJ; Lynch V; Clynes M
    Int J Cancer; 2012 Aug; 131(4):911-23. PubMed ID: 21953030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of haptoglobin and alpha₁-acid glycoprotein glycosylation in the sera of small cell and non-small cell lung cancer patients.
    Ferens-Sieczkowska M; Kratz EM; Kossowska B; Passowicz-Muszyńska E; Jankowska R
    Postepy Hig Med Dosw (Online); 2013 Aug; 67():828-36. PubMed ID: 24018448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
    Jiang ZF; Wang M; Xu JL
    Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
    Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
    Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mass spectrometric identification, characterization and validation of the haptoglobin β-chain protein as a lung cancer serum biomarker.
    Ayyub A; Saleem M; Musharraf SG; Naz M; Tariq A; Hashmi N
    Mol Med Rep; 2015 Sep; 12(3):3755-3762. PubMed ID: 26005016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
    Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
    J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates.
    Boccellino M; Pinto F; Ieluzzi V; Giovane A; Quagliuolo L; Fariello C; Coppola M; Carlucci A; Santini M; Ferati K; Bexheti-Ferati A; Giordano A; Di Domenico M
    J Cell Physiol; 2019 Dec; 234(12):23798-23806. PubMed ID: 31180588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
    Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
    Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
    J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
    Takada M; Masuda N; Matsuura E; Kusunoki Y; Matui K; Nakagawa K; Yana T; Tuyuguchi I; Oohata I; Fukuoka M
    Br J Cancer; 1995 Jan; 71(1):160-5. PubMed ID: 7529525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
    Lamy PJ; Grenier J; Kramar A; Pujol JL
    Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
    Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
    Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum carcinoembryonic antigen, neuron-specific enolase as biomarkers for diagnosis of nonsmall cell lung cancer.
    Dong Y; Zheng X; Yang Z; Sun M; Zhang G; An X; Pan L; Zhang S
    J Cancer Res Ther; 2016 Oct; 12(Supplement):34-36. PubMed ID: 27721249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
    Pujol JL; Boher JM; Grenier J; Quantin X
    Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
    Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
    Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
    van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
    Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.